Drugs / JTM201
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07292025 | Jun 2023 → Apr 2024 | diplegia of upper limb | Jetema Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06246552 | Oct 2024 → Jun 2025 | — | Jetema USA Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JTM201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07292025 ↗ |
| Known as | Botulinum Toxin Type A | “JTM201 (Botulinum Toxin Type A) to Treat Moderate or Severe Glabellar Lines” NCT06246552 ↗ |
| Route | Intramuscular | “JTM201 will be injected via IM in 5 glabellar location” NCT06246552 ↗ |